Pharmaceuticals, Biotechnology and Life Sciences
Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is further strengthening its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for biotechs, pharmaceutical companies and academics.
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
Sygnature Discovery has developed an AR molecular visualisation prototype, meaning that scientists could soon be rotating virtual molecules in the world around them.
Sygnature Discovery has moved its US office to the heart of the Cambridge–Boston biotech hub, describing it as a small but a significant move, as it will have more than 100 pharma/biotech companies within a mile of the new office, and many more in the wider Boston–Cambridge area.